Ellenbecker Investment Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.43M | Sell |
5,702
-186
| -3% | -$40K | 0.17% | 38 |
|
|
2026
Q1 | $1.28M | Buy |
5,888
+279
| +5% | +$61.9K | 0.17% | 36 |
|
|
2025
Q4 | $1.28M | Buy |
5,609
+275
| +5% | +$62.6K | 0.18% | 35 |
|
|
2025
Q3 | $1.24M | Buy |
5,334
+44
| +0.8% | +$8.96K | 0.18% | 37 |
|
|
2025
Q2 | $982K | Buy |
5,290
+7
| +0.1% | +$1.3K | 0.16% | 40 |
|
|
2025
Q1 | $1.11M | Buy |
5,283
+627
| +13% | +$122K | 0.2% | 38 |
|
|
2024
Q4 | $827K | Sell |
4,656
-730
| -14% | -$134K | 0.15% | 49 |
|
|
2024
Q3 | $1.06M | Sell |
5,386
-675
| -11% | -$126K | 0.2% | 42 |
|
|
2024
Q2 | $1.04M | Buy |
6,061
+82
| +1% | +$13.6K | 0.21% | 39 |
|
|
2024
Q1 | $1.09M | Buy |
5,979
+95
| +2% | +$16.4K | 0.23% | 38 |
|
|
2023
Q4 | $911K | Buy |
5,884
+153
| +3% | +$22.3K | 0.21% | 42 |
|
|
2023
Q3 | $854K | Sell |
5,731
-72
| -1% | -$10.6K | 0.22% | 40 |
|
|
2023
Q2 | $781K | Buy |
5,803
+83
| +1% | +$12.2K | 0.2% | 43 |
|
|
2023
Q1 | $911K | Buy |
5,720
+42
| +0.7% | +$6.42K | 0.25% | 35 |
|
|
2022
Q4 | $917K | Buy |
5,678
+718
| +14% | +$110K | 0.27% | 34 |
|
|
2022
Q3 | $665K | Buy |
4,960
+286
| +6% | +$41K | 0.21% | 35 |
|
|
2022
Q2 | $715K | Buy |
4,674
+132
| +3% | +$20.2K | 0.22% | 34 |
|
|
2022
Q1 | $736K | Buy |
4,542
+33
| +0.7% | +$4.79K | 0.21% | 36 |
|
|
2021
Q4 | $610K | Buy |
4,509
+45
| +1% | +$5.32K | 0.17% | 36 |
|
|
2021
Q3 | $481K | Sell |
4,464
-35
| -0.8% | -$4K | 0.15% | 39 |
|
|
2021
Q2 | $507K | Sell |
4,499
-31
| -0.7% | -$3.49K | 0.17% | 34 |
|
|
2021
Q1 | $490K | Buy |
4,530
+93
| +2% | +$9.95K | 0.17% | 38 |
|
|
2020
Q4 | $475K | Buy |
4,437
+8
| +0.2% | +$769 | 0.18% | 38 |
|
|
2020
Q3 | $388K | Buy |
4,429
+72
| +2% | +$6.78K | 0.17% | 41 |
|
|
2020
Q2 | $428K | Buy |
4,357
+171
| +4% | +$15.1K | 0.21% | 34 |
|
|
2020
Q1 | $319K | Buy |
4,186
+5
| +0.1% | +$426 | 0.2% | 37 |
|
|
2019
Q4 | $370K | Sell |
4,181
-98
| -2% | -$8.14K | 0.19% | 39 |
|
|
2019
Q3 | $324K | Buy |
4,279
+283
| +7% | +$19.4K | 0.18% | 43 |
|
|
2019
Q2 | $291K | Buy |
3,996
+348
| +10% | +$27.4K | 0.17% | 45 |
|
|
2019
Q1 | $294K | Buy |
3,648
+243
| +7% | +$19.9K | 0.19% | 47 |
|
|
2018
Q4 | $314K | Buy |
+3,405
| New | +$299K | 0.24% | 40 |
|
Other funds holding ABBV
Ellenbecker Investment Group's ABBV Position: Q2 2026 in Review
Ellenbecker Investment Group reduced its AbbVie (ABBV) stake by 3.2% in Q2 2026, selling an estimated $40K and leaving 5,702 shares worth $1.43M. The position accounts for 0.17% of the portfolio, ranked #38.
Ellenbecker Investment Group first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Ellenbecker Investment Group held 5,702 shares of AbbVie worth $1.43M as of Q2 2026.
- Ellenbecker Investment Group sold 186 AbbVie shares in Q2 2026, an estimated $40K.
- AbbVie made up 0.17% of Ellenbecker Investment Group's portfolio in Q2 2026, its #38 holding.
- Ellenbecker Investment Group first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Ellenbecker Investment Group's 13F filing for Q2 2026, filed 27 Jul 2026.